Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.15 USD | -4.24% | -0.54% | +48.36% |
Jun. 04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
Jun. 03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
Evolution of the average Target Price on NovoCure Limited
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering NovoCure Limited
Wedbush | |
Piper Sandler | |
Wells Fargo Securities | |
Evercore ISI | |
HC Wainwright | |
SVB Securities LLC | |
JPMorgan Chase | |
Truist Securities | |
Loop Capital | |
Oppenheimer | |
Mizuho Securities | |
Northland Securities | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- NVCR Stock
- Consensus NovoCure Limited